349 results on '"Dimier-Poisson, Isabelle"'
Search Results
52. The molecular targets of ivermectin and lotilaner in the human louse Pediculus humanus humanus: New prospects for the treatment of pediculosis
53. Major Role for CD8+T Cells in the Protection Against Toxoplasma gondii Following Dendritic Cell Vaccination
54. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine
55. Induction of protective immunity against toxoplasmosis in mice by immunization with Toxoplasma gondii RNA
56. Key Limitations and New Insights Into the Toxoplasma gondii Parasite Stage Switching for Future Vaccine Development in Human, Livestock, and Cats
57. 846 Neospora caninum – an immunotherapeutic protozoan against solid cancers
58. Corrigendum: Blockade of IL-33R/ST2 Signaling Attenuates Toxoplasma gondii Ileitis Depending on IL-22 Expression
59. Distinct molecular targets for macrocyclic lactone and isoxazoline insecticides in the human louse: new prospects for the treatment of pediculosis
60. Exploration and Modulation of Antibody Fragment Biophysical Properties by Replacing the Framework Region Sequences
61. Caractérisation des récepteurs canaux ioniques dépendants chez le Pou Pediculus humanus corporis
62. Des imidazopyridazines ciblant la TgCDPK1 diminuent fortement l’infection par Toxoplasma gondii dans un modèle murin de toxoplasmose congénitale
63. Développement d’un vaccin sous-unitaire innovant contre la toxoplasmose des animaux de la faune sauvage en captivité
64. The European Platform for animal experimentation to study veterinary and emerging diseases and to develop new vaccine against pathogens
65. WITHDRAWN: Babesia divergens glycosylphosphatidylinositols modulate blood coagulation and induce Th2-biased cytokine profiles in antigen presenting cells
66. Immune response against toxoplasmosis--some recent updates RH: Toxoplasma gondii immune response.
67. MyD88 is crucial for the development of a protective CNS immune response to Toxoplasma gondii infection
68. Engineering and Functional Evaluation of Neutralizing Antibody Fragments Against Congenital Toxoplasmosis.
69. Toxoplasma gondii : un espoir de vaccin ?
70. The European platform for animal experimentation on infectious diseases, to study animal and emerging diseases and the immune response to vaccination against pathogens
71. Étude de l’impact du paracétamol sur la réponse immunitaire induite et comportementale lors d’une toxoplasmose aiguë et chronique chez la souris
72. Développement et validation d'outils de raffinements (3Rs) pour les modèles murins (lignée C57bl/6) en infectiologie expérimentale
73. Attenuated vaccine strain of Toxoplasma gondii: immunostimulatory properties and control of cryptosporidiosis
74. Study of innate immune responses of antigen presenting cells from farm animals to a vaccine platform against neosporosis
75. Des imidazopyridazines ciblant la TgCDPK1 diminuent fortement la transmission de Toxoplasma gondii dans un modèle murin de toxoplasmose congénitale
76. Blockade of IL-33R/ST2 Signaling Attenuates Toxoplasma gondii Ileitis Depending on IL-22 Expression
77. Vaccins muqueux
78. Maîtrise de la douleur en relation avec le comportement observé (stress) liés à une hyperthermie infectieuse parasitaire ou bactérienne chez la souris
79. Caractérisation moléculaire et fonctionnelle des canaux ioniques ligand-dépendants chez Pediculus humanus
80. Plateformes vaccinales anti-apicomplexes
81. Targeted Delivery of Toxoplasma gondii Antigens to Dendritic Cells Promote Immunogenicity and Protective Efficiency against Toxoplasmosis
82. Vaccin innovant contre la néosporose combinant les antigènes complets et des adjuvants glycolipidiques de Neospora dans une plateforme nanoparticulaire
83. Projet éthique et bien-être animal: contrôle de la douleur liée à l'hyperthermie au cours du processus infectieux
84. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro
85. Residence time and uptake of porous and cationic maltodextrin-based nanoparticles in the nasal mucosa: Comparison with anionic and cationic nanoparticles
86. Impact of Site-Specific Conjugation of ScFv to Multifunctional Nanomedicines Using Second Generation Maleimide
87. Targeted Delivery of Toxoplasma gondii Antigens to Dendritic Cells Promote Immunogenicity and Protective Efficiency against Toxoplasmosis
88. Interaction between Toxoplasma Gondii and Enterocyte
89. Synthetic parasites: a successful mucosal nanoparticle vaccine against Toxoplasma congenital infection in mice
90. Vaccin innovant contre la néosporose combinant les antigènes complets et des adjuvants glycolipidiques de Neospora dans une plateforme nanoparticulaire
91. Des imidazo[1,2-b]pyridazines ciblant la CDPK1 de Toxoplasma gondii diminuent drastiquement la charge parasitaire dans un modèle de toxoplasmose murine aiguë
92. Plateformes vaccinales anti-apicomplexes
93. Des imidazo[1,2-b]pyridazines ciblant la CDPK1 comme nouvelle chimiothérapie anti-toxoplasmose
94. Imidazo[1,2-b]pyridazines targeting TgCDPK1 as new anti-Toxoplasma gondii chemotherapeutic treatments
95. Des imidazo[1,2-b]pyridazines ciblant la CDPK1 de Toxoplasma gondii diminuent drastiquement la charge parasitaire dans un modèle de toxoplasmose murine aiguë
96. Développement de nouveaux inhibiteurs de TgCDPK1 à visée anti-toxoplasmique
97. Bioeliminable porous nanoparticles for protein delivery in airway mucosa
98. Conception, synthèse et évaluation de nouveaux inhibiteurs de TgCDPK1 à visée anti-toxoplasmique
99. Targeted delivery of Toxoplasma antigens to dendritic cells promote immunogenicity and protective efficiency against Toxoplasmosis
100. Nasal administration of antigens using maltodextrin nanoparticles: a mechanistic study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.